Anacor Pharmaceutica (ANAC) 99.25 $ANAC Stock Market

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 12:08 PM

Anacor Pharmaceutica (ANAC) 99.25 $ANAC

Stock Market News for May 23, 2016
Zacks Equity Research - Zacks Investment Research - Mon May 23, 9:10AM CDT
Benchmarks closed in positive territory on Friday following speculations that indications of a Fed rate hike signal that the economy may be strengthening
TSLA: 193.39 (-3.27), HD: 128.01 (+0.41), FB: 114.90 (+0.99), PFE: 34.53 (+0.06), WMT: 71.96 (+0.21), INTC: 32.81 (+0.52), GS: 152.13 (+3.99), IBM: 154.17 (+1.25), AMAT: 24.45 (+0.48), TGT: 70.05 (+1.19), ANAC: 99.25 (+0.08), GOOGL: 707.93 (-2.54), FL: 53.57 (+0.02), BRK.B: 145.26 (+1.32), AAPL: 95.75 (+0.20)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc.
BusinessWire - Fri May 20, 9:10PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or "the Company"

(Nasdaq: ANAC) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer"

.
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Into Whether the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share is Fair to Shareholders
BusinessWire - Fri May 20, 3:43PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

ANACOR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Anacor Pharmaceuticals, Inc. (ANAC) Over the Proposed Sale of the Company to Pfizer Inc.
BusinessWire - Fri May 20, 1:08PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company"

(Nasdaq:ANAC) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $5.2 billion.
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 59.05 (+0.16), TTPH: 4.00 (+0.04), TRVN: 6.11 (+0.16), ADRO: 10.73 (+0.50), ANAC: 99.25 (+0.08)

Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 1.31 (-0.01), ARLZ: 3.32 (-0.02), ANAC: 99.25 (+0.08), ATHX: 2.02 (+0.07)

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Anacor Pharmaceuticals, Inc. -ANAC
PR Newswire - Thu May 19, 9:10PM CDT
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or "the Company"

(Nasdaq- ANAC-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Pfizer, Inc. ("Pfizer"

.
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 59.05 (+0.16), TRVN: 6.11 (+0.16), TTPH: 4.00 (+0.04), VRTX: 86.35 (+1.13), ADRO: 10.73 (+0.50), AMGN: 152.15 (+2.34), ANAC: 99.25 (+0.08)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Regarding the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share
BusinessWire - Thu May 19, 12:33PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

Anacor Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Pfizer, Inc.
BusinessWire - Wed May 18, 3:28PM CDT
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor"

(NASDAQ: ANAC) concerning the merger with Pfizer, Inc. Under the terms of the agreement, valued at approximately $5.2 billion, Anacor shareholders will only receive $99.25 in cash per share held.
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

Ryan & Maniskas, LLP Announces Investigation of Anacor Pharmaceuticals, Inc.
PR Newswire - Wed May 18, 9:41AM CDT
Ryan & Maniskas, LLP is investigating potential claims against the board of directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company"

(NASDAQ: ANAC) concerning possible breaches of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Pfizer Inc. in a transaction valued at approximately $5.2 billion.
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Tue May 17, 4:32PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company"

(Nasdaq: ANAC) relating to the proposed buyout of the Company by Pfizer Inc.
ANAC: 99.25 (+0.08)

INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation Concerning the Fairness of the Sale of Anacor Pharmaceuticals, Inc. to Pfizer Inc. for $99.25 Per Share -- ANAC
PR Newswire - Tue May 17, 1:44PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

Block & Leviton LLP Investigates Anacor Pharmaceuticals Inc., Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Pfizer Inc.
PR Newswire - Tue May 17, 12:26PM CDT
Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of Anacor Pharmaceuticals Inc. ("Anacor" or the "Company"

(NASDAQ: ANAC) concerning the proposed acquisition of the Company by Pfizer Inc. ("Pfizer"

in an all-cash transaction.
PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08)

Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead
Sweta Killa - Zacks Investment Research - Tue May 17, 10:40AM CDT
Pfizer struck a deal to acquire the skin drug maker Anacor Pharmaceuticals for $5.2 billion that sent biotech ETFs higher.
AGN: 230.23 (+1.68), PBE: 37.26 (+0.48), SBIO: 23.10 (+0.33), FBT: 90.53 (+1.13), XBI: 54.01 (+0.71), PFE: 34.53 (+0.06), BBH: 103.13 (+1.52), IBB: 260.13 (+3.57), ANAC: 99.25 (+0.08)

Pfizer to Buy Anacor, Add Eczema Treatment to Portfolio
Arpita Dutt - Zacks Investment Research - Tue May 17, 7:13AM CDT
Pfizer (PFE) maintained its 2016 guidance but expects the deal to be earnings dilutive in 2017 and accretive thereafter.
MDVN: 59.05 (+0.16), AGN: 230.23 (+1.68), PFE: 34.53 (+0.06), ANAC: 99.25 (+0.08), BMY: 72.65 (+0.34)

Business Highlights
By The Associated Press - AP - Mon May 16, 4:46PM CDT
___
ZTS: 47.65 (+0.32), AGN: 230.23 (+1.68), AMZN: 719.48 (+8.88), PFE: 34.53 (+0.06), GM: 29.79 (+0.47), ANAC: 99.25 (+0.08), BRK.B: 145.26 (+1.32), BRK.A: 217,770.00 (+1,504.00)

Apple, Anacor and Tribune Publishing climb, Trevena skids
AP - Mon May 16, 3:21PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday:
TRVN: 6.11 (+0.16), TPUB: 13.96 (+0.17), MCK: 184.23 (+2.70), PFE: 34.53 (+0.06), MRD: 16.89 (+0.15), TEX: 22.28 (+0.28), ANAC: 99.25 (+0.08), MRO: 15.17 (+0.42), AAPL: 95.75 (+0.20)

SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BusinessWire - Mon May 16, 3:10PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Anacor Pharmaceuticals, Inc. ("Anacor" or the "Company"

(Nasdaq: ANAC) relating to the proposed buyout of the Company by Pfizer Inc.
ANAC: 99.25 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

Vitamin Angels Drives Global Nutrition Advancements

Navigating the Waters of Global Nutrition Bet you never thought a vitamin program could spearhead the front lines of healthcare, huh? Vitamin Angels are grinding away under the radar, shifting the landscape for maternal and child nutrition. At the heart of it all is their vision to make UNIMMAP multiple micronutrient supplementation (MMS) a staple in the global playbook....

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

EMCO's New Automated Facility Could Shake Industry

A Novel Leap in Production Capacity EMCO Industries just put a solid foot on the accelerator with their brand-new, shiny, fully automated plant over in Claremore, Oklahoma. If you're glancing at heavy-duty trailer springs, you can't ignore the fact that this is a multimillion-dollar investment. Heck, this monstrous 30,000-square-foot facility more than doubles what EMCO...

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...